Affiliation:
1. Dalian Municipal Central Hospital Affiliated of Dalian University of Technology, Dalian, 116021, China
2. School of Life
and Pharmaceutical Sciences, Dalian University of Technology, Panjin, 124221, China
3. Affiliated Hospital of
Changchun University of Traditional Chinese Medicine, Changchun, 130021, China
Abstract
Background::
As a malignant tumor, osteosarcoma (OS) ranks first place among adolescent
cancers and is susceptible to developing resistance to chemotherapeutic agents. Differently,
traditional Chinese medicine (TCM) has multiple pharmacodynamic targets and complex biological
components, which can inhibit tumor survival and drug resistance and gradually play an important
role in the treatment of sarcoma.
Methods::
This study is to systematically evaluate the safety and efficacy of TCM combined with
chemotherapy performed in the clinical treatment of OS. Based on multiple mainstream databases,
eleven articles on the relationship between natural products and chemotherapy involving 656 patients
were selected from all the literature published as of June 2022. Revman 5.4 software was
used for a comprehensive search analysis, supplemented by established exclusion criteria, the
Jadad scale, and the evaluation methods provided by Cochrane.
Results::
The efficiency of TCM combined with chemotherapy was significantly increased compared
with chemical drugs alone [OR=2.56, 95% CI (1.36,4.79), Z=2.92, P=0.003]. Meanwhile,
the adverse reactions such as nausea and vomiting, hepatotoxicity, and hematological changes
caused by chemical drugs were alleviated correspondingly.
Conclusion::
This study indicates that the mode of TCM combined with chemotherapy sheds light
on the clinical treatment of OS, which is much better than the one-way mode.
Funder
Dalian Life and Health Guidance Plan Project
Basic Research Funds for Central Universities
Liaoning Provincial Natural Science Fund
Jilin Provincial Development and Reform Commission Industrial Technology Research and Development Project
Publisher
Bentham Science Publishers Ltd.